John Evans
Patrimonio netto: 34 M $ in data 31/08/2026
Patrimonio netto: 34 M $ in data 31/08/2026
Attualmente, John Evans occupa la posizione di amministratore delegato e direttore presso Beam Therapeutics, Inc. e Venture Partner presso ARCH Venture Partners LLC. Mr. Evans è anche nel consiglio di Verve Therapeutics, Inc. In precedenza ha occupato la posizione di vicepresidente dello sviluppo aziendale e delle operazioni presso Agios Pharmaceuticals, Inc. e di contatto per le relazioni con gli investitori presso Infinity Pharmaceuticals, Inc. Il signor Evans ha conseguito una laurea presso l'Università della Pennsylvania, una laurea presso la Yale University e un MBA presso la Wharton School dell'Università della Pennsylvania.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 30/06/2026 | 1.150.205 ( 1,11% ) | 34 M $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| BEAM THERAPEUTICS INC. | Amministratore Delegato | 01/01/2017 |
Blink Therapeutics, Inc.
Blink Therapeutics, Inc. BiotechnologyHealth Technology Develops novel platform to generate therapeutic and diagnostic monoclonal antibodies | Amministratore Delegato | - |
Orbital Therapeutics, Inc.
Orbital Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops RNA-based medicines | Direttore/Membro del Consiglio | - |
| Società | Posizione | Fine |
|---|---|---|
| PRIME MEDICINE, INC. | Direttore/Membro del Consiglio | 13/09/2022 |
| VERE THER | Direttore/Membro del Consiglio | 04/08/2022 |
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Investitore di Private Equity | 31/03/2021 |
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/04/2017 |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Corporate Officer/Principal | 01/07/2006 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 12 |
|---|---|
ARCH Venture Partners LLC
ARCH Venture Partners LLC Investment ManagersFinance ARCH Venture Partners invests in disruptive science companies located in the United States. The firm target companies operating in the fields of biotechnology and technology sectors. It provides financing for early stage capital requirements with a minimum investment size of $0.05 million and also makes co-investments. | Finance |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer | Health Technology |
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beam Therapeutics, Inc.
Beam Therapeutics, Inc. BiotechnologyHealth Technology Operate as a biotechnology company that develops precision genetic medicines, gene editing and delivery technologies | Health Technology |
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
Blink Therapeutics, Inc.
Blink Therapeutics, Inc. BiotechnologyHealth Technology Develops novel platform to generate therapeutic and diagnostic monoclonal antibodies | Health Technology |
Prime Medicine, Inc.
Prime Medicine, Inc. BiotechnologyHealth Technology Develops CRISPR gene editing technology | Health Technology |
Orbital Therapeutics, Inc.
Orbital Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops RNA-based medicines | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale